View ValuationChengDa Pharmaceuticals 将来の成長Future 基準チェック /06現在、 ChengDa Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長18.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Apr 28Full year 2025 earnings released: CN¥0.079 loss per share (vs CN¥0.18 loss in FY 2024)Full year 2025 results: CN¥0.079 loss per share (improved from CN¥0.18 loss in FY 2024). Revenue: CN¥406.4m (up 22% from FY 2024). Net loss: CN¥11.9m (loss narrowed 58% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.お知らせ • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang Chinaお知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.Reported Earnings • Oct 28Third quarter 2025 earnings released: EPS: CN¥0.026 (vs CN¥0.10 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.026 (down from CN¥0.10 in 3Q 2024). Revenue: CN¥102.6m (up 29% from 3Q 2024). Net income: CN¥3.95m (down 74% from 3Q 2024). Profit margin: 3.8% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025New Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 39% per year over the past 5 years.Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CN¥0.094 (vs CN¥0.043 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.094 (up from CN¥0.043 in 2Q 2024). Revenue: CN¥106.1m (up 68% from 2Q 2024). Net income: CN¥14.2m (up 118% from 2Q 2024). Profit margin: 13% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Declared Dividend • Jul 07Dividend of CN¥0.20 announcedDividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments.お知らせ • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).New Risk • May 16New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years.Reported Earnings • Apr 25First quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.12 profit in 1Q 2024)First quarter 2025 results: CN¥0.009 loss per share (down from CN¥0.12 profit in 1Q 2024). Revenue: CN¥76.3m (down 24% from 1Q 2024). Net loss: CN¥1.40m (down 108% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.お知らせ • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang ChinaNew Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.7% per year over the past 5 years. High level of non-cash earnings (27% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change).Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CN¥24.29, the stock trades at a trailing P/E ratio of 52.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 57% over the past three years.お知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.分析記事 • Oct 08ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With EarningsChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) shareholders have had their patience rewarded with a 42% share price...分析記事 • Oct 08There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price JumpThe ChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) share price has done very well over the last month, posting an...お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.分析記事 • Sep 03ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for ChengDa Pharmaceuticals Co., Ltd.'s ( SZSE:301201 ) stock hasn't...Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.分析記事 • Jul 05ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last YearChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) has announced that on 10th of July, it will be paying a dividend...Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past year.お知らせ • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 27% over the past year.Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past year.お知らせ • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 24% over the past year.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 36% over the past year.Valuation Update With 7 Day Price Move • Jul 06Investor sentiment deteriorates as stock falls 36%After last week's 36% share price decline to CN¥26.09, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 65% over the past year.お知らせ • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.お知らせ • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥88.4m (down 6.6% from 3Q 2021). Net income: CN¥27.0m (up 38% from 3Q 2021). Profit margin: 31% (up from 21% in 3Q 2021). The increase in margin was driven by lower expenses.Reported Earnings • Aug 15Second quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥108.6m (up 15% from 2Q 2021). Net income: CN¥38.9m (up 99% from 2Q 2021). Profit margin: 36% (up from 21% in 2Q 2021). The increase in margin was primarily driven by higher revenue.お知らせ • May 24ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022.お知らせ • May 12ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021.お知らせ • Apr 20ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend for the Year 2021ChengDa Pharmaceuticals Co., Ltd. announced final dividend proposal of CNY 4.50000000 per 10 shares (tax included) for the year 2021.Valuation Update With 7 Day Price Move • Mar 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥102, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China.Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 27% share price gain to CN¥91.01, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ChengDa Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測SZSE:301201 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026458-4-1346N/A12/31/2025406-12-3534N/A9/30/2025374-52-17537N/A6/30/2025352-40-2255N/A3/31/2025309-48-298-32N/A12/31/2024333-28-25829N/A9/30/202439870-189104N/A6/30/202441287-132150N/A3/31/202441390-74162N/A12/31/202341491-33192N/A9/30/202336676-20181N/A6/30/202336171-98100N/A3/31/2023405100-98107N/A1/1/2023411106-15848N/A9/30/2022432122-1369N/A6/30/2022438115-11644N/A3/31/2022436106-8379N/A1/1/2022416100-5683N/A9/30/2021396126N/AN/AN/A12/31/202037312165129N/A12/31/201929454N/A68N/A12/31/20182037N/A55N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 301201の予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 301201の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 301201の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 301201の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 301201の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 301201の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 21:24終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ChengDa Pharmaceuticals Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Apr 28Full year 2025 earnings released: CN¥0.079 loss per share (vs CN¥0.18 loss in FY 2024)Full year 2025 results: CN¥0.079 loss per share (improved from CN¥0.18 loss in FY 2024). Revenue: CN¥406.4m (up 22% from FY 2024). Net loss: CN¥11.9m (loss narrowed 58% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 28ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
お知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026
New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026
Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Yongzhou Hu was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 12Chengda Pharmaceuticals Co., Ltd. Approves Board AppointmentsChengDa Pharmaceuticals Co., Ltd. approved the appointment of Hu Yongzhou, independent director, Jiang Lin, independent director, Zhou Junming, independent director.
Reported Earnings • Oct 28Third quarter 2025 earnings released: EPS: CN¥0.026 (vs CN¥0.10 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.026 (down from CN¥0.10 in 3Q 2024). Revenue: CN¥102.6m (up 29% from 3Q 2024). Net income: CN¥3.95m (down 74% from 3Q 2024). Profit margin: 3.8% (down from 19% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2025 Results on Oct 28, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025
New Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 39% per year over the past 5 years.
Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CN¥0.094 (vs CN¥0.043 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.094 (up from CN¥0.043 in 2Q 2024). Revenue: CN¥106.1m (up 68% from 2Q 2024). Net income: CN¥14.2m (up 118% from 2Q 2024). Profit margin: 13% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Declared Dividend • Jul 07Dividend of CN¥0.20 announcedDividend of CN¥0.20 is the same as last year. Ex-date: 10th July 2025 Payment date: 10th July 2025 Dividend yield will be 0.9%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 36 years, indicating a lack of growth and stability in payments.
お知らせ • Jul 02ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.5% average weekly change).
New Risk • May 16New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 33% per year over the past 5 years.
Reported Earnings • Apr 25First quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.12 profit in 1Q 2024)First quarter 2025 results: CN¥0.009 loss per share (down from CN¥0.12 profit in 1Q 2024). Revenue: CN¥76.3m (down 24% from 1Q 2024). Net loss: CN¥1.40m (down 108% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 23% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 25ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025ChengDa Pharmaceuticals Co., Ltd., Annual General Meeting, May 16, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Jiaxing, Zhejiang China
New Risk • Apr 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.7% per year over the past 5 years. High level of non-cash earnings (27% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change).
Valuation Update With 7 Day Price Move • Apr 01Investor sentiment improves as stock rises 26%After last week's 26% share price gain to CN¥24.29, the stock trades at a trailing P/E ratio of 52.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 57% over the past three years.
お知らせ • Mar 31ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
お知らせ • Dec 31ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.21 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.21 in 3Q 2023). Revenue: CN¥79.8m (down 15% from 3Q 2023). Net income: CN¥15.2m (down 52% from 3Q 2023). Profit margin: 19% (down from 34% in 3Q 2023). The decrease in margin was primarily driven by lower revenue.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥20.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year.
分析記事 • Oct 08ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With EarningsChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) shareholders have had their patience rewarded with a 42% share price...
分析記事 • Oct 08There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price JumpThe ChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) share price has done very well over the last month, posting an...
お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 28%After last week's 28% share price gain to CN¥21.80, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 14% over the past year.
分析記事 • Sep 03ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfDespite posting some strong earnings, the market for ChengDa Pharmaceuticals Co., Ltd.'s ( SZSE:301201 ) stock hasn't...
Reported Earnings • Aug 28Second quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.063 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.063 in 2Q 2023). Revenue: CN¥63.1m (down 2.0% from 2Q 2023). Net income: CN¥6.53m (down 33% from 2Q 2023). Profit margin: 10% (down from 15% in 2Q 2023). The decrease in margin was primarily driven by higher expenses.
分析記事 • Jul 05ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last YearChengDa Pharmaceuticals Co., Ltd. ( SZSE:301201 ) has announced that on 10th of July, it will be paying a dividend...
Declared Dividend • Jul 05Dividend of CN¥0.20 announcedShareholders will receive a dividend of CN¥0.20. Ex-date: 10th July 2024 Payment date: 10th July 2024 Dividend yield will be 1.1%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (34% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 26 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 57% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 29ChengDa Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.4% average weekly change).
Reported Earnings • Apr 22First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 1Q 2023). Revenue: CN¥100.9m (down 1.3% from 1Q 2023). Net income: CN¥18.6m (down 5.1% from 1Q 2023). Profit margin: 19% (in line with 1Q 2023).
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥17.46, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 38% over the past year.
お知らせ • Mar 30ChengDa Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q1, 2024 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CN¥22.92, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 27% over the past year.
Buy Or Sell Opportunity • Feb 23Now 22% overvaluedOver the last 90 days, the stock has fallen 31% to CN¥19.33. The fair value is estimated to be CN¥15.89, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 29%.
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to CN¥17.62, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 48% over the past year.
お知らせ • Dec 30ChengDa Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024ChengDa Pharmaceuticals Co., Ltd. announced that they will report fiscal year 2023 results on Apr 22, 2024
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥27.63, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 24% over the past year.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.21 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥93.7m (up 5.9% from 3Q 2022). Net income: CN¥31.8m (up 18% from 3Q 2022). Profit margin: 34% (up from 31% in 3Q 2022).
お知らせ • Sep 30ChengDa Pharmaceuticals Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023ChengDa Pharmaceuticals Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.25 (in line with 2Q 2022). Revenue: CN¥64.4m (down 41% from 2Q 2022). Net income: CN¥9.71m (down 75% from 2Q 2022). Profit margin: 15% (down from 36% in 2Q 2022). The decrease in margin was driven by lower revenue.
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥24.43, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 36% over the past year.
Valuation Update With 7 Day Price Move • Jul 06Investor sentiment deteriorates as stock falls 36%After last week's 36% share price decline to CN¥26.09, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 65% over the past year.
お知らせ • Jul 06ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023ChengDa Pharmaceuticals Co., Ltd. announced final cash dividend/10 shares (tax included) of CNY 3.00000000 on A shares for the year 2022. Record date is July 6, 2023. Ex-date is July 7, 2023. Payment date is July 7, 2023.
お知らせ • May 19+ 1 more updateChengda Pharmaceuticals Co., Ltd. Announces Directorate AppointmentsChengDa Pharmaceuticals Co., Ltd. at its Annual General Meeting of 2022 on 16 May 2023, approved appointment of Lu Jin as non-independent director and appointment of Cui Sunliang as independent directors.
Reported Earnings • Apr 24First quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥0.30 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.20 (down from CN¥0.30 in 1Q 2022). Revenue: CN¥102.2m (down 5.9% from 1Q 2022). Net income: CN¥19.6m (down 25% from 1Q 2022). Profit margin: 19% (down from 24% in 1Q 2022).
Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.27 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.28 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥88.4m (down 6.6% from 3Q 2021). Net income: CN¥27.0m (up 38% from 3Q 2021). Profit margin: 31% (up from 21% in 3Q 2021). The increase in margin was driven by lower expenses.
Reported Earnings • Aug 15Second quarter 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.27 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.44 (up from CN¥0.27 in 2Q 2021). Revenue: CN¥108.6m (up 15% from 2Q 2021). Net income: CN¥38.9m (up 99% from 2Q 2021). Profit margin: 36% (up from 21% in 2Q 2021). The increase in margin was primarily driven by higher revenue.
お知らせ • May 24ChengDa Pharmaceuticals Co., Ltd. Announces Cash Dividend for 2021, Dividend Payable on 27 May 2022ChengDa Pharmaceuticals Co., Ltd. announced cash dividend per 10 shares (tax included) of CNY 4.500000 for 2021. The dividend payable on 27 May 2022, with a record date of 26 May 2022.
お知らせ • May 12ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2021ChengDa Pharmaceuticals Co., Ltd. at its annual general meeting held on 9 May 2022 approved cash dividend per 10 shares (tax included) of CNY 2.0000000 for 2021.
お知らせ • Apr 20ChengDa Pharmaceuticals Co., Ltd. Announces Final Dividend for the Year 2021ChengDa Pharmaceuticals Co., Ltd. announced final dividend proposal of CNY 4.50000000 per 10 shares (tax included) for the year 2021.
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to CN¥102, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China.
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improved over the past weekAfter last week's 27% share price gain to CN¥91.01, the stock trades at a trailing P/E ratio of 70.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in China.